...
首页> 外文期刊>Prescrire international >axicabtagene ciloleucel (yescarta0) in certain types of lymphoma when other treatment options have been exhausted-A CAR T-cell therapy that increases the chances of survival but frequently provokes serious adverse effects
【24h】

axicabtagene ciloleucel (yescarta0) in certain types of lymphoma when other treatment options have been exhausted-A CAR T-cell therapy that increases the chances of survival but frequently provokes serious adverse effects

机译:在某些类型的淋巴瘤中,当其他治疗方案已经耗尽的汽车T细胞疗法时,轴颈特异菜(Yescarta0)在疲惫不堪的T细胞疗法增加,这增加了生存的机会,但经常引起严重的不良影响

获取原文
获取原文并翻译 | 示例
           

摘要

Patients with relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma, after several lines of therapy, have a poor prognosis. As of mid-2019, there is no consensus on subsequent treatment. Chemotherapy is sometimes offered, but it has not been shown to extend survival more than appropriate symptomatic care. Axicabtagene ciloleucel (Kite Pharma) is a CAR (chimeric antigen receptor) T-cell therapy. Treatment entails harvesting T cells from the patient, sending them to a manufacturing centre where they are genetically modified to express a chimeric receptor on their surface that recognises CD19 (an antigen present on the surface of the neoplastic and other B cells), then infusing the modified T cells into the patient.
机译:患有复发或难治性弥漫性大的B细胞淋巴瘤或原发性纵隔大B细胞淋巴瘤,经过几种治疗,预后差。 截至2019年中期,随后的治疗没有共识。 有时提供化疗,但尚未显示出于适当的症状性护理的生存。 AxicabTagene Ciloleucel(风筝药物)是汽车(嵌合抗原受体)T细胞疗法。 治疗需要从患者收集T细胞,将它们发送到制造中心,在那里遗传修饰的制造中心以表达其表面上的嵌合受体识别CD19的表面(肿瘤和其他B细胞表面上存在的抗原),然后输注 改性T细胞进入患者。

著录项

  • 来源
    《Prescrire international》 |2019年第208期|共2页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号